ProQR (PRQR) Price & Analysis

Compare

1,088 Followers

PRQR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.07 - $4.62

Previous CloseN/A

Volume75.97K

Average Volume (3M)256.81K

Market Cap

$213.58M

Enterprise Value$91.96M

Total Cash (Recent Filing)$132.41M

Total Debt (Recent Filing)$16.85M

Price to Earnings (P/E)―

Beta1.76

Next Earnings

Nov 05, 2025

EPS Estimate

-0.12

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.14

Shares Outstanding105,212,524

10 Day Avg. Volume360,267

30 Day Avg. Volume256,810

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.43

Enterprise Value/Revenue4.84

Enterprise Value/Gross Profit5.03

Enterprise Value/Ebitda-3.38

Forecast

1Y Price Target

$7.00

Price Target Upside216.74% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Clinical TrialsProQR's shift from preclinical promise to clinical execution marks an important step with AX-0810’s Clinical Trial Application.

PartnershipsPartnership with Eli Lilly underscores platform value and opens the door for milestone payments down the road.

Platform ValidationA two-fold reduction in bile acid levels might powerfully validate ProQR’s EON RNA editing platform by targeting NTCP.

Bears Say

Development TimelineAxiomer RNA editing platform will generate first clinical data in 2025.

FundingRett opportunity is underappreciated; PRQR received $9.1M in funding from the Rett Syndrome Research Trust for AX-2402.

Market PerceptionRett opportunity is underappreciated and PRQR received funding from the Rett Syndrome Research Trust, which could open the door to other common RTT mutations.

ProQR News

ProQR Therapeutics reports Q2 EPS (EUR 0.21) vs. (EUR 0.13) last year

Reports revenue EUR 3.8M vs. EUR 6.3M last year. “We continued to execute across our pipeline in the...

15d ago

PRQR

ProQR Therapeutics sees cash runway into mid-2027

At June 30, 2025, ProQR held cash and cash equivalents of approximately EUR 119.8 million, compared to EUR...

15d ago

PRQR

ProQR’s Strategic Advancements and Clinical Prospects Drive Buy Rating

In a report released on August 8, Ananda Ghosh from H.C. Wainwright maintained a Buy rating on ProQR,...

11d ago

PRQR

ProQR Reports Q2 2025 Financial Results Amid Rising R&D Costs

ProQR ( ($PRQR) ) has shared an announcement. On August 7, 2025, ProQR Therapeutics N.V. announced its financial...

15d ago

PRQR

ProQR Therapeutics price target raised to $5 from $4 at Evercore ISI

Evercore ISI raised the firm’s price target on ProQR Therapeutics (PRQR) to $5 from $4 and keeps an...

1M ago

PRQR

ProQR Submits CTA for Phase 1 Study of AX-0810

ProQR ( ($PRQR) ) just unveiled an update. On June 26, 2025, ProQR Therapeutics announced the submission of...

2M ago

PRQR

ProQR Shareholders Approve Key Resolutions at Annual Meeting

The latest announcement is out from ProQR ( ($PRQR) ). On June 3, 2025, ProQR Therapeutics N.V. held...

3M ago

PRQR

ProQR Therapeutics Reports Q1 2025 Financial Results

ProQR Therapeutics BV ( ($PRQR) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

PRQR

ProQR Therapeutics price target lowered to $9 from $15 at Oppenheimer

Oppenheimer analyst Andreas Argyrides lowered the firm’s price target on ProQR Therapeutics (PRQR) to $9 from $15 and...

3M ago

PRQR

ProQR’s Innovative RNA Editing Platform and Promising AX-0810 Program Drive Buy Rating

H.C. Wainwright analyst Andrew Fein has maintained their bullish stance on PRQR stock, giving a Buy rating on...

4M ago

PRQR

ProQR Reports Q1 2025 Financial Results Amid Rising R&D Costs

ProQR ( ($PRQR) ) has issued an announcement. ProQR Therapeutics N.V. announced its financial results for the first...

4M ago

PRQR

ProQR Therapeutics reports Q1 EPS (EUR 0.10) vs (EUR 0.09) last year

Reports Q1 revenue EUR 4.519M vs EUR 4.450M last year. “ProQR entered 2025 in a position of strength,...

4M ago

PRQR

PRQR Upcoming Earnings Report: What to Expect?

ProQR Therapeutics BV (PRQR) is scheduled to report 1st quarter earnings on 05/08/2025. Regarding Q1 estimates, Wall Street...

4M ago

PRQR

ProQR Schedules Annual Shareholders Meeting for June 3, 2025

An announcement from ProQR ( ($PRQR) ) is now available. On May 1, 2025, ProQR Therapeutics announced its...

4M ago

PRQR

PRQR FAQ

What was ProQR’s price range in the past 12 months?

ProQR lowest stock price was $1.07 and its highest was $4.62 in the past 12 months.

What is ProQR’s market cap?

ProQR’s market cap is $213.58M.

When is ProQR’s upcoming earnings report date?

ProQR’s upcoming earnings report date is Nov 05, 2025 which is in 75 days.

How were ProQR’s earnings last quarter?

ProQR released its earnings results on Aug 07, 2025. The company reported -$0.14 earnings per share for the quarter, the consensus estimate of -$0.14 by $0.

Is ProQR overvalued?

According to Wall Street analysts ProQR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does ProQR pay dividends?

ProQR does not currently pay dividends.

What is ProQR’s EPS estimate?

ProQR’s EPS estimate is -0.12.

How many shares outstanding does ProQR have?

ProQR has 105,212,524 shares outstanding.

What happened to ProQR’s price movement after its last earnings report?

ProQR reported an EPS of -$0.14 in its last earnings report, expectations of -$0.14. Following the earnings report the stock price went down -0.485%.

Which hedge fund is a major shareholder of ProQR?

Currently, no hedge funds are holding shares in PRQR

ProQR Stock Smart Score

Underperform

Fundamentals

Return on Equity

-75.99%

Trailing 12-Months

Asset Growth

27.61%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

ProQR

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

ProQR (PRQR) Earnings & Revenues

Historic Earnings Reports

PRQR Stock 12 Month Forecast

Average Price Target

$7.00

▲(216.74% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","3.25":"$3.25","6.5":"$6.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.08,2.8430769230769233,3.6061538461538465,4.36923076923077,5.132307692307693,5.895384615384616,6.658461538461538,7.421538461538462,8.184615384615384,8.947692307692307,9.71076923076923,10.473846153846154,11.236923076923077,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.08,2.4584615384615387,2.836923076923077,3.2153846153846155,3.5938461538461537,3.9723076923076923,4.350769230769231,4.729230769230769,5.107692307692307,5.486153846153846,5.864615384615385,6.243076923076923,6.621538461538462,{"y":7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.08,2.073846153846154,2.0676923076923077,2.0615384615384618,2.0553846153846154,2.0492307692307694,2.043076923076923,2.036923076923077,2.0307692307692307,2.0246153846153847,2.0184615384615383,2.0123076923076924,2.006153846153846,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.82,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.76,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.73,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.73,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.65,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.33,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.78,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.01,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >